Citations

Clear

37 citation(s) found for "Anderson, Brian".

Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma
Xi, Mian , Hallemeier, Christopher L. , Merrell, Kenneth W. , Murphy, Mariela A. Blum, Ho, Linus, Hofstetter, Wayne L. , Mehran, Reza J. , Lee, Jeffrey H. , Weston, Brian , Komaki, Ritsuko , Ajani, Jaffer A. , Hallemeier, Christopher Leigh , Liao, Zhongxing , Murphy, Mariela Blum, Bhutani, Manoop S. , Maru, Dipen Maheshbhai , Lin, Steven H. , Ajani, Jaffer A

Mayo Clinic

Annals of Surgery | June 17, 2017 | Volume: 268 | Issue: 2 | Pages: 289-295

10.1097/sla.0000000000002352 | PMID 28628563 Get It

Objective: To discern recurrence risk stratification and investigate its influence on postoperative surveillance in patients with esophageal adenocarcinoma (EAC) after neoadjuvant chemoradiotherapy (CRT). Background: Reports documenting recurrence risk stratification in EAC after neoadjuvant CRT are scarce. Methods: Between 1998 and 2014, 601 patients with EAC who underwent neoadjuvant CRT followed by esophagectomy were included for analysis. The pattern, site, timing, and frequency of the first recurrence and potential prognostic factors for developing recurrences were analyzed. This cohort was used as the training set to propose a recurrence risk stratification system, and the stratification was further validated in another cohort of 172 patients. Results: A total of 150 patients (25.0%) achieved pathologic complete response (pCR) after neoadjuvant CRT and the rest were defined as the non-pCR group (n = 451) in the training cohort. After a median follow-up of 63.6 months, the pCR group demonstrated a significantly lower locoregional (4.7% vs 19.1%) and distant recurrence rate (22.0% vs.44.6%) than the non-pCR group (P < 0.001). Based on independent prognostic factors, patients were stratified into 4 recurrence risk categories: pCR with clinical stage I/II, pCR with clinical stage III, non-pCR with pN0, and non-pCR with pN+, with corresponding 5-year recurrence-free survival rates of 88.7%, 65.8%, 55.3%, and 33.0%, respectively (P < 0.001). The risk stratification was reproducible in the validation cohort. Conclusions: We proposed a recurrence risk stratification system for EAC patients based on pathologic response and pretreatment clinical stage. Risk-based postoperative surveillance strategies could be developed for different risk categories.
Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.
Tosoian, Jeffrey J. , Sundi, Debasish , Chapin, Brian F. , Chappidi, Meera R. , Karnes, R. Jeffrey , Ross, Ashley E. , Antonarakis, Emmanuel S. , Alam, Ridwan , Glavaris, Stephanie A. , Pienta, Kenneth J , Tran, Phuoc T , Schaeffer, Edward M.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 2_suppl | Pages: 103-103

10.1200/jco.2016.34.2_suppl.103 Get It

103 Background: Beginning in 2014, the National Comprehensive Cancer Network (NCCN) recognized very high-risk (VHR) prostate cancer (cT3b-T4, or primary Gleason pattern 5, or more than 4 biopsy cores with Gleason score 8-10, or multiple HR features) as a classification distinct from high-risk (HR) disease. Using prospectively collected institutional data, we describe contemporary treatment patterns and short-term outcomes in the VHR population. Methods: Men who underwent radical prostatectomy (RP) between January 2010 and June 2015 were identified using the Johns Hopkins RP database, and trends in management were compared across the study period. Pathological and short-term clinical outcomes were assessed in men with VHR cancer. Non organ-confined disease (NOCD) was defined as ≥ pT3 disease or lymph node positivity, persistent postoperative PSA as ≥ 0.2 ng/mL, and biochemical recurrence (BCR) as a PSA ≥ 0.2 ng/mL following an initial undetectable postoperative PSA. Results: During the study period, 4,954 men underwent RP, of which 161 (3.2%) men had VHR cancer at diagnosis. The annual proportion of men who underwent RP with VHR cancer increased over the study period (chronologically 1.8%, 1.0%, 3.3%, 4.1%, 5.6%, and 5.2%; p<0.001). Sixteen percent of men with VHR disease were enrolled in pre-surgical clinical trials, with an increase from 0% of men in 2010 to 19.1% in 2015 (p=0.11). At RP, 39% of the VHR cohort had seminal vesicle invasion, 26% had lymph node involvement, and a total of 74% had NOCD. Following surgery, 33% of men had PSA persistence, and 40% experienced either PSA persistence or BCR during follow-up (median 13.4 months). Of 136 men with at least one follow-up assessment, 15 (11.0%) developed metastasis; 33% of the cohort was treated with radiation therapy, 42% with androgen deprivation, and 15% with docetaxel. Conclusions: The VHR population carries the greatest risk of clinical progression following local treatment. Over the past five years, we have observed increasing surgical treatment and clinical trial enrollment at our institution. Continued assessment of post-operative interventions and outcomes will help to facilitate counseling and establish point estimates from which to power clinical trials.
Gliosarcoma with Primary Skull Base Invasion
Nguyen, Quoc‐Bao D. , Perry, Avital , Graffeo, Christopher S. , Jentoft, Mark E. , Morris, Padraig P., Gompel, Jamie J. Van , Nesvick, Cody L. , O'Neill, Brian P, Van Gompel, Jamie J , Raghunathan, Aditya , O’Neill, Brian Patrick , Morris, Jonathan M.

Mayo Clinic

Case Reports in Radiology | December 8, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-6

10.1155/2016/1762195 | PMID 28053799 Get It

Gliosarcoma is an uncommon variant of glioblastoma, which commonly demonstrates dural attachment. However, skull base invasion is rarely seen with this entity. Herein, we report a 44-year-old female patient diagnosed with primary intracranial gliosarcoma extensively invading the skull base and muscles of mastication. She presented to our institution with a three-month history of difficult right jaw opening and retro-orbital pressure and one week of severe right-sided postauricular headache. Head CT demonstrated a 6 cm mass with marked bony erosion. Brain MRI at a one-week interval more clearly characterized tumor extension through the right orbit and muscles of mastication, with overall growth to 7 cm and worsening midline shift. The patient underwent a right frontotemporal craniotomy for gross total resection. Pathology confirmed the diagnosis of gliosarcoma, IDH-wildtype (WHO grade IV). Her postoperative course was uneventful and she was discharged at preoperative neurologic baseline. To our knowledge, this is the third reported case of a primary intracranial gliosarcoma with direct invasion of skull base, brain parenchyma, and extracranial compartment. However, this is the first report case of primary GS invading the surrounding musculature and orbit. This case report highlights the rapid aggressiveness of gliosarcomas and further a prior undescribed radiographic and anatomic finding of skull base invasion with this entity.
Radiogenomics to characterize regional genetic heterogeneity in glioblastoma
Hu, Leland , Ning, Shuluo , Eschbacher, Jennifer , Baxter, Leslie C. , Gaw, Nathan , Ranjbar, Sara , Plasencia, Jonathan D. , Dueck, Amylou C. , Peng, Sen, Smith, Kris A. , Karis, John P. , Quarles, C. Chad , Loftus, Joseph C. , Jenkins, Robert B. , Sicotte, Hugues , Kollmeyer, Thomas M. , Elmquist, William F. , Frakes, David , Swanson, Kristin R. , Tran, Nhan L. , Mitchell, J. Ross , Eschbacher, Jennifer M., Plasencia, Jonathan, Nakaji, Peter , O'Neill, Brian P, Elmquist, William, Hoxworth, Joseph M. , Sarkaria, Jann, Dueck, A. C. , Baxter, Leslie C. , Wu, Teresa , O’Neill, Brian Patrick , Sarkaria, Jann N. , Swanson, Kristin R , Li, Jing , Kollmeyer, Thomas , Tran, Nhan L

Mayo Clinic

Neuro-Oncology | August 9, 2016 | Volume: 19 | Issue: 1 | Pages: 128-137

10.1093/neuonc/now135 | PMID 27502248 Get It

AbstractBackgroundGlioblastoma (GBM) exhibits profound intratumoral genetic heterogeneity. Each tumor comprises multiple genetically distinct clonal populations with different therapeutic sensitivities. This has implications for targeted therapy and genetically informed paradigms. Contrast-enhanced (CE)-MRI and conventional sampling techniques have failed to resolve this heterogeneity, particularly for nonenhancing tumor populations. This study explores the feasibility of using multiparametric MRI and texture analysis to characterize regional genetic heterogeneity throughout MRI-enhancing and nonenhancing tumor segments.MethodsWe collected multiple image-guided biopsies from primary GBM patients throughout regions of enhancement (ENH) and nonenhancing parenchyma (so called brain-around-tumor, [BAT]). For each biopsy, we analyzed DNA copy number variants for core GBM driver genes reported by The Cancer Genome Atlas. We co-registered biopsy locations with MRI and texture maps to correlate regional genetic status with spatially matched imaging measurements. We also built multivariate predictive decision-tree models for each GBM driver gene and validated accuracies using leave-one-out-cross-validation (LOOCV).ResultsWe collected 48 biopsies (13 tumors) and identified significant imaging correlations (univariate analysis) for 6 driver genes: EGFR, PDGFRA, PTEN, CDKN2A, RB1, and TP53. Predictive model accuracies (on LOOCV) varied by driver gene of interest. Highest accuracies were observed for PDGFRA (77.1%), EGFR (75%), CDKN2A (87.5%), and RB1 (87.5%), while lowest accuracy was observed in TP53 (37.5%). Models for 4 driver genes (EGFR, RB1, CDKN2A, and PTEN) showed higher accuracy in BAT samples (n = 16) compared with those from ENH segments (n = 32).ConclusionMRI and texture analysis can help characterize regional genetic heterogeneity, which offers potential diagnostic value under the paradigm of individualized oncology.
Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)
Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W., Galanis, E., Shah, Sunjay, Abrams, Ross A. , Curran, Walter J. , Buckner, Jan C. , Shaw, Edward G. , O'Neill, Brian P, Galanis, Eva, Shah, Sunjay A, O’Neill, Brian Patrick , Giannini, Caterina

Mayo Clinic

Neuro-Oncology Practice | November 5, 2015 | Volume: 2 | Issue: 4 | Pages: 199-204

10.1093/nop/npv031 | PMID 26640699 Get It

Abstract Background Pilocytic astrocytoma is a rare tumor in adults. This report is of a prospective clinical trial with long-term follow-up. Methods Between 1986 and 1994, 20 eligible adults with supratentorial pilocytic astrocytomas were enrolled in a prospective intergroup trial of radiotherapy (RT) after biopsy (3 patients) or observation after gross (11 patients) or subtotal (6 patients) resection. Results At the time of analysis (median follow-up, 20.8 years), 2 patients (10%) have died and 18 patients (90%) are alive. Neurologic and cognitive function were stable or improved over time for the majority of patients. No toxic effects of treatment or malignant transformations have been recorded at last follow-up. For the entire cohort the 20-year time to progression and overall survival rates are 95% and 90% respectively. The cause of death (2.2 and 16.1 years after enrollment) in both patients was unrelated to tumor although both were biopsy-only patients. One subtotally resected tumor progressed 1 month after enrollment requiring P32 injection into an enlarging cyst. Because of further progression this patient required RT 18 months later. This patient is alive without evidence of progression 18 years after RT. Conclusion The long-term follow-up results of this prospective trial confirm that adults with pilocytic astrocytomas have a favorable prognosis with regard to survival and neurologic function. Close observation is recommended for adults with pilocytic astrocytomas, reserving RT for salvage, as the majority remain stable after gross or subtotal resection and no adjuvant therapy.
The Metastatic Spine Disease Multidisciplinary Working Group Algorithms
Robinson, Clifford G. , Meyer, Jeffrey , Gangi, Afshin , Callstrom, Matthew R. , Chao, Samuel T. , Tine, Brian Andrew Van, Bruel, Brian M., Long, Jeremiah R. , Timmerman, Robert , Buchowski, Jacob M. , Jennings, Jack W. , Wallace, Adam N, Tran, Nam D, Van Tine, Brian A, Long, Jeremiah, Timmerman, Robert D, Wallace, Adam N. , Tran, Nam , Morris, Jonathan M. , Robinson, Clifford

Mayo Clinic

The Oncologist | September 10, 2015 | Volume: 20 | Issue: 10 | Pages: 1205-1215

10.1634/theoncologist.2015-0085 | PMID 26354526 Get It

AbstractThe Metastatic Spine Disease Multidisciplinary Working Group consists of medical and radiation oncologists, surgeons, and interventional radiologists from multiple comprehensive cancer centers who have developed evidence- and expert opinion-based algorithms for managing metastatic spine disease. The purpose of these algorithms is to facilitate interdisciplinary referrals by providing physicians with straightforward recommendations regarding the use of available treatment options, including emerging modalities such as stereotactic body radiation therapy and percutaneous tumor ablation. This consensus document details the evidence supporting the Working Group algorithms and includes illustrative cases to demonstrate how the algorithms may be applied.Implications for Practice:The Metastatic Spine Disease Multidisciplinary Working Group algorithms can facilitate interdisciplinary referrals by providing physicians with straightforward recommendations regarding available treatment options, including emerging modalities such as stereotactic body radiation therapy and percutaneous tumor ablation.
The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion
Stemland, Christopher, Witte, Jürgen, Colquhoun, Douglas A. , Durieux, Marcel E. , Langman, Loralie J., Balireddy, Ravi K., Thammishetti, Swapna, Abel, Mark F. , Anderson, Brian J.

Mayo Clinic

Pediatric Anesthesia | September 15, 2012 | Volume: 23 | Issue: 1 | Pages: 51-57

10.1111/pan.12021 | PMID 22978825 Get It

SummaryBackgroundThe optimal methadone dosing regimen for children undergoing spinal surgery is uncertain because of sparse pediatric pharmacokinetic data and a paucity of analgesic effect data. The minimum effective analgesic concentration of methadone in opioid naïve adults is 58 mcg·L−1.MethodsAdolescents aged 12–19 years undergoing idiopathic scoliosis correction were administered 0.25 mg·kg−1 racemic methadone IV prior to surgical incision. Arterial blood samples for methadone assay were obtained at 0 min, 5 min, 10 min, 15 min, 20 min, 40 min, 1 h, 2 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, and 48 h. Compartment analysis was undertaken using nonlinear mixed effects models. Parameter estimates were standardized to a 70‐kg person using allometric models.ResultsA three‐compartment linear disposition model best described observed time–concentration profiles. Population parameter estimates (between‐subjects variability) were central volume (V1) 19.1 (126%) L 70 kg−1, peripheral volumes of distribution V2 65.5 (60%) L 70 kg−1, V3 485 (23%) L 70 kg−1, clearance (CL) 9.3 (11%) L·h−1·70 kg−1, and inter‐compartment clearances Q2 282 (95%) L·h−1 70 kg−1, Q3 139 (42%) L·h−1 70 kg−1. The terminal elimination half‐life was 44.4 h. The mean observed methadone concentration was <58 mcg·L−1 by the first hour after administration.ConclusionsCurrent pharmacokinetic parameter estimates in adolescents are similar to those reported in adults. Methadone undergoes rapid redistribution after bolus administration. This may result in plasma concentrations that provide inadequate analgesia postoperatively. We would suggest following the bolus (0.25 mg.kg‐1) with an infusion (0.1–0.15 mg·kg−1·h−1 for 4 h) during spinal surgery to ensure adequate plasma concentrations for 24 h.